New drug JSKN016HC enters first human tests for advanced cancers
NCT ID NCT07475559
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called JSKN016HC in about 42 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must be in fairly good health and have at least one measurable tumor outside the brain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Scientia Clinical Research Ltd
Sydney, New South Wales, 2031, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral drug elraglusib aims to tame advanced solid tumors
- Engineered virus targets Hard-to-Treat cancers from the inside
- Engineered herpes virus takes aim at Hard-to-Treat cancers
- Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
- New drug combo aims to shrink Hard-to-Treat tumors
- MRNA cancer shot shows promise in early trial